Pending – SyBleu

CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT

Quality of a cellular graft

SYBLEU, Inc. (OTC PINK: SYBE) is a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics. We actively pursue strategic acquisitions and in-licensing opportunities to expand our intellectual property portfolio and seek to form strategic partnerships to bring these technologies to market.

Home

About Us

Investor Relations

Company News

Contact Us

Home

About Us

Investor Relations

Company News

Contact Us

© COPYRIGHT 2023. ALL RIGHTS RESERVED.